Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group

The high cost of biological drugs for patients with inflammatory bowel disease (IBD) considerably impacts on health-care budgets. Since the patent of biological products expired, cheaper biosimilars have entered the market. Available data coming from real-world cohorts and clinical trials indicate that the efficacy and safety of biosimilars is comparable to that of the originator drugs. Treating IBD patients with a biosimilar may be complicated by the risk of the nocebo effect, a negative effect of a pharmacological or non-pharmacological treatment, induced by patients ’s expectations and unrelated to the physiological action of the treatment.

Source: Digestive and Liver Disease - December 3, 2019 Category: Gastroenterology Authors: Ferdinando D ’Amico, Lieven Pouillon, Marjorie Argollo, Ailsa Hart, Gionata Fiorino, Elena Vegni, Simona Radice, Daniela Gilardi, Maria Fazio, Salvo Leone, Stefanos Bonovas, Fernando Magro, Silvio Danese, Laurent Peyrin-Biroulet Tags: Review Article Source Type: research